Basilea Pharmaceutica AG Allschwil to Acquire the Rights to Fosmanogepix from Amplyx Pharmaceuticals Inc Call Transcript

Nov 13, 2023 / 03:00PM GMT
Operator

Ladies and gentlemen, welcome to the Basilea Pharmaceutica Acquisition of Fosmanogepix Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.

David Veitch - Basilea Pharmaceutica AG - CEO

Thank you very much. Hello. I'm David Veitch, CEO of Basilea, and I'd like to welcome you to our conference call and webcast to discuss the acquisition of the broad spectrum antifungal, fosmanogepix, from Amplyx Pharmaceuticals, an affiliate of Pfizer, which we have reported this morning as an ad hoc announcement. The ad hoc release is available on our website at basilea.com.

I would also like to mention that this call contains forward-looking statements. Joining me on our call today are Dr. Marc Engelhardt, our Chief Medical Officer; and Adesh Kaul, our Chief Financial Officer.

Basilea is a leading

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot